Phase II Study of Tandem High Dose Melphalan Supported, by Peripheral Blood Stem Cell Support in Waldenstrom’s Macroglobulinemia (WM).

Patients must have diagnosis of WM based on demonstration of IgM monoclonal gammopathy with monoclonal light chain components in serum and/or urine, presence of monoclonal lymphocytic infiltration in BM, lymph nodes, spleen and/or liver. Those with large cell component with marked IgM serum levels >1 g/dl are also eligible. Patients must have quantifiable IgM; patients must have either clinical symptoms of WM, advanced tumor mass, or progressive disease (with specific requirements listed in the protocol). Patients must have PS of 0-2 and be < 70 years of age; prior chemo. and/or RT is allowed if 4 weeks have elapsed since ending treatment; patients must not have recent (< 6 months) MI, CHF or arrhythmia refractory to therapy; patients must have adequate pulmonary function and be negative for hepatitis B and HIV.